Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly BeatInvestors Business Daily • 05/01/24
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid salesCNBC • 05/01/24
Pfizer first-quarter results top estimates, drugmaker boosts full-year profit outlookMarket Watch • 05/01/24
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid declineInvezz • 05/01/24
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks InsteadThe Motley Fool • 04/30/24
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerBusiness Wire • 04/29/24
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerBusiness Wire • 04/29/24
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual MeetingBusiness Wire • 04/29/24